FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168738314> ?p ?o ?g. }

• W2168738314 endingPage "25" @default.
• W2168738314 startingPage "25" @default.
• W2168738314 abstract "In this study, we report on the synthesis, radiolabeling, and biological evaluation of two new somatostatin-14 (SS14) analogs, modified with the universal chelator DOTA. We were interested to investigate if and to what extent such radiotracer prototypes may be useful for targeting sst1-5-expressing tumors in man but, most importantly, to outline potential drawbacks and benefits associated with their use.AT1S and AT2S (DOTA-Ala1-Gly2-c[Cys3-Lys4-Asn5-Phe6-Phe7-Trp8/DTrp8-Lys9-Thr10-Phe11-Thr12-Ser13-Cys14-OH], respectively) were synthesized on the solid support and labeled with 111In. The sst1-5 affinity profile of AT1S/AT2S was determined by receptor autoradiography using [Leu8,dTrp22,125I-Tyr25]SS28 as radioligand. The ability of AT2S to stimulate sst2 or sst3 internalization was qualitatively analyzed by an immunofluorescence-based internalization assay using hsst2- or hsst3-expressing HEK293 cells. Furthermore, the internalization of the radioligands [111In]AT1S and [111In]AT2S was studied at 37 °C in AR4-2J cells endogenously expressing sst2. The in vivo stability of [111In]AT1S and [111In]AT2S was tested by high-performance liquid chromatography analysis of mouse blood collected 5 min after radioligand injection, and biodistribution was studied in normal mice. Selectively for [111In]AT2S, biodistribution was further studied in SCID mice bearing AR4-2J, HEK293-hsst2A+, -hsst3+ or -hsst5+ tumors.The new SS14-derived analogs were obtained by solid phase peptide synthesis and were easily labeled with 111In. Both SS14 conjugates, AT1S, and its DTrp8 counterpart, AT2S, showed a pansomatostatin affinity profile with the respective hsst1-5 IC50 values in the lower nanomolar range. In addition, AT2S behaved as an agonist for sst2 and sst3 since it stimulated receptor internalization. The 111In radioligands effectively and specifically internalized into rsst2A-expressing AR4-2J cells with [111In]AT2S internalizing faster than [111In]AT1S. Ex vivo mouse blood analysis revealed a rapid degradation of both radiopeptides in the bloodstream with the DTrp8 analog showing higher stability. Biodistribution results in healthy mice were consistent with these findings with only [111In]AT2S showing specific uptake in the sst2-rich pancreas. Biodistribution of [111In]AT2S in tumor-bearing mice revealed receptor-mediated uptake in the AR4-2J (1.82 ± 0.36 %ID/g - block 0.21 ± 0.17 %ID/g at 4 h post injection (pi)), the HEK293-hsst2A+ (1.49 ± 0.2 %ID/g - block 0.27 ± 0.20 %ID/g at 4 h pi), the HEK293-hsst3+ (1.24 ± 0.27 %ID/g - block 0.32 ± 0.06 %ID/g at 4 h pi), and the HEK293-hsst5+ tumors (0.41 ± 0.12 %ID/g - block 0.22 ± 0.006 %ID/g at 4 h pi). Radioactivity washed out from blood and background tissues via the kidneys.This study has revealed that the native SS14 structure can indeed serve as a motif for the development of promising pansomatostatin-like radiotracers. Further peptide stabilization is required to increase in vivo stability and, consequently, to enhance in vivo delivery and tumor targeting." @default.
• W2168738314 created "2016-06-24" @default.
• W2168738314 creator A5007991478 @default.
• W2168738314 creator A5022226042 @default.
• W2168738314 creator A5029897786 @default.
• W2168738314 creator A5035742901 @default.
• W2168738314 creator A5040369608 @default.
• W2168738314 creator A5048733664 @default.
• W2168738314 creator A5061906450 @default.
• W2168738314 creator A5079838266 @default.
• W2168738314 creator A5090743837 @default.
• W2168738314 date "2012-01-01" @default.
• W2168738314 modified "2023-10-12" @default.
• W2168738314 title "[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study" @default.
• W2168738314 cites W1480909434 @default.
• W2168738314 cites W1584743295 @default.
• W2168738314 cites W1968407572 @default.
• W2168738314 cites W1987132507 @default.
• W2168738314 cites W1989520943 @default.
• W2168738314 cites W1995922082 @default.
• W2168738314 cites W1998767852 @default.
• W2168738314 cites W2000324027 @default.
• W2168738314 cites W2001213717 @default.
• W2168738314 cites W2004023055 @default.
• W2168738314 cites W2005674134 @default.
• W2168738314 cites W2009248375 @default.
• W2168738314 cites W2016356824 @default.
• W2168738314 cites W2018042027 @default.
• W2168738314 cites W2040127137 @default.
• W2168738314 cites W2045681528 @default.
• W2168738314 cites W2064522544 @default.
• W2168738314 cites W2066524003 @default.
• W2168738314 cites W2068379336 @default.
• W2168738314 cites W2071310612 @default.
• W2168738314 cites W2076152939 @default.
• W2168738314 cites W2076665586 @default.
• W2168738314 cites W2081397564 @default.
• W2168738314 cites W2102603000 @default.
• W2168738314 cites W2119674738 @default.
• W2168738314 cites W2170518806 @default.
• W2168738314 cites W4234756450 @default.
• W2168738314 cites W4239520211 @default.
• W2168738314 cites W4250058955 @default.
• W2168738314 cites W4255956523 @default.
• W2168738314 doi "https://doi.org/10.1186/2191-219x-2-25" @default.
• W2168738314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3407795" @default.
• W2168738314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22682002" @default.
• W2168738314 hasPublicationYear "2012" @default.
• W2168738314 type Work @default.
• W2168738314 sameAs 2168738314 @default.
• W2168738314 citedByCount "19" @default.
• W2168738314 countsByYear W21687383142013 @default.
• W2168738314 countsByYear W21687383142014 @default.
• W2168738314 countsByYear W21687383142015 @default.
• W2168738314 countsByYear W21687383142017 @default.
• W2168738314 countsByYear W21687383142018 @default.
• W2168738314 countsByYear W21687383142019 @default.
• W2168738314 countsByYear W21687383142020 @default.
• W2168738314 countsByYear W21687383142022 @default.
• W2168738314 crossrefType "journal-article" @default.
• W2168738314 hasAuthorship W2168738314A5007991478 @default.
• W2168738314 hasAuthorship W2168738314A5022226042 @default.
• W2168738314 hasAuthorship W2168738314A5029897786 @default.
• W2168738314 hasAuthorship W2168738314A5035742901 @default.
• W2168738314 hasAuthorship W2168738314A5040369608 @default.
• W2168738314 hasAuthorship W2168738314A5048733664 @default.
• W2168738314 hasAuthorship W2168738314A5061906450 @default.
• W2168738314 hasAuthorship W2168738314A5079838266 @default.
• W2168738314 hasAuthorship W2168738314A5090743837 @default.
• W2168738314 hasBestOaLocation W21687383141 @default.
• W2168738314 hasConcept C126322002 @default.
• W2168738314 hasConcept C139770010 @default.
• W2168738314 hasConcept C150903083 @default.
• W2168738314 hasConcept C153911025 @default.
• W2168738314 hasConcept C170493617 @default.
• W2168738314 hasConcept C185592680 @default.
• W2168738314 hasConcept C202751555 @default.
• W2168738314 hasConcept C207001950 @default.
• W2168738314 hasConcept C2776297358 @default.
• W2168738314 hasConcept C2777807558 @default.
• W2168738314 hasConcept C2779931791 @default.
• W2168738314 hasConcept C2989005 @default.
• W2168738314 hasConcept C55493867 @default.
• W2168738314 hasConcept C67847695 @default.
• W2168738314 hasConcept C71924100 @default.
• W2168738314 hasConcept C80115893 @default.
• W2168738314 hasConcept C86803240 @default.
• W2168738314 hasConcept C98274493 @default.
• W2168738314 hasConceptScore W2168738314C126322002 @default.
• W2168738314 hasConceptScore W2168738314C139770010 @default.
• W2168738314 hasConceptScore W2168738314C150903083 @default.
• W2168738314 hasConceptScore W2168738314C153911025 @default.
• W2168738314 hasConceptScore W2168738314C170493617 @default.
• W2168738314 hasConceptScore W2168738314C185592680 @default.
• W2168738314 hasConceptScore W2168738314C202751555 @default.
• W2168738314 hasConceptScore W2168738314C207001950 @default.
• W2168738314 hasConceptScore W2168738314C2776297358 @default.
• W2168738314 hasConceptScore W2168738314C2777807558 @default.

• next